# Jarushka Naidoo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jarushka-naidoo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,890 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 62 |
| i10-index | 146 |
| Last Known Institution | Johns Hopkins University |
| OpenAlex ID | https://openalex.org/A5044692746 |
| ORCID iD | https://orcid.org/0000-0002-3470-8686 |
| Works | 494 |

## Researcher papers

- [Neoadjuvant PD-1 Blockade in Resectable Lung Cancer](https://scholariq.org/papers/neoadjuvant-pd-1-blockade-in-resectable-lung-cancer/)
- [Genome-wide cell-free DNA fragmentation in patients with cancer](https://scholariq.org/papers/genome-wide-cell-free-dna-fragmentation-in-patients-with-cancer/)
- [Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy](https://scholariq.org/papers/pneumonitis-in-patients-treated-with-anti-programmed-death-1-programmed-death/)
- [Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer](https://scholariq.org/papers/evolution-of-neoantigen-landscape-during-immune-checkpoint-blockade-in-non-small/)
- [Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events](https://scholariq.org/papers/society-for-immunotherapy-of-cancer-sitc-clinical-practice-guideline-on-immune/)
- [Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/management-of-immunotherapy-related-toxicities-version-1-2019-nccn-clinical/)
- [Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers](https://scholariq.org/papers/transcriptional-programs-of-neoantigen-specific-til-in-anti-pd-1-treated-lung/)
- [Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer](https://scholariq.org/papers/multisystem-immune-related-adverse-events-associated-with-immune-checkpoint/)
- [NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020](https://scholariq.org/papers/nccn-guidelines-insights-management-of-immunotherapy-related-toxicities-version/)
- [Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial](https://scholariq.org/papers/four-year-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc-an/)
- [Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors](https://scholariq.org/papers/pneumonitis-in-non-small-cell-lung-cancer-patients-receiving-immune-checkpoint/)
- [Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer](https://scholariq.org/papers/neoadjuvant-nivolumab-plus-ipilimumab-in-resectable-non-small-cell-lung-cancer/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Johns Hopkins University](https://scholariq.org/institutions/johns-hopkins-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.